Autoimmune Biotech Xencor Files for a $69 Million IPO
Published: Oct 11, 2013
Xencor, a clinical-stage biotech developing treatments for severe autoimmune and allergic diseases and cancer, filed on Friday with the SEC to raise up to $69 million in an initial public offering.
Help employers find you! Check out all the jobs and post your resume.